Medico Remedies Limited (MEDICO.NS)
INR 51.12
(2.22%)
INR 51.12
(2.22%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.44 Billion INR | 3.19% |
| 2022 | 1.4 Billion INR | 18.66% |
| 2021 | 1.18 Billion INR | -3.3% |
| 2020 | 1.22 Billion INR | 38.08% |
| 2019 | 886.36 Million INR | -9.27% |
| 2018 | 976.87 Million INR | 60.08% |
| 2017 | 610.24 Million INR | 12.14% |
| 2016 | 544.18 Million INR | -18.39% |
| 2015 | 666.83 Million INR | 30.78% |
| 2014 | 509.89 Million INR | 13.67% |
| 2013 | 448.58 Million INR | 32.95% |
| 2012 | 337.42 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 307.98 Million INR | -25.47% |
| 2023 Q1 | 314.69 Million INR | 12.43% |
| 2023 Q2 | 423.55 Million INR | 34.59% |
| 2023 Q4 | 413.22 Million INR | 38.8% |
| 2023 FY | 1.44 Billion INR | 3.19% |
| 2023 Q3 | 297.72 Million INR | -29.71% |
| 2022 Q4 | 279.91 Million INR | -27.94% |
| 2022 Q1 | 331.37 Million INR | 11.93% |
| 2022 Q2 | 404.62 Million INR | 22.1% |
| 2022 Q3 | 388.46 Million INR | -3.99% |
| 2022 FY | 1.4 Billion INR | 18.66% |
| 2021 Q2 | 295.36 Million INR | 1.59% |
| 2021 Q4 | 296.06 Million INR | -1.74% |
| 2021 Q1 | 290.74 Million INR | -4.35% |
| 2021 FY | 1.18 Billion INR | -3.3% |
| 2021 Q3 | 301.32 Million INR | 2.02% |
| 2020 FY | 1.22 Billion INR | 38.08% |
| 2020 Q2 | 307.98 Million INR | 0.0% |
| 2020 Q3 | 303.96 Million INR | -1.31% |
| 2020 Q4 | 303.96 Million INR | 0.0% |
| 2020 Q1 | 307.98 Million INR | 34.38% |
| 2019 Q4 | 229.18 Million INR | 0.0% |
| 2019 FY | 886.36 Million INR | -9.27% |
| 2019 Q2 | 213.99 Million INR | 0.0% |
| 2019 Q1 | 213.99 Million INR | -23.87% |
| 2019 Q3 | 229.18 Million INR | 7.1% |
| 2018 Q4 | 281.09 Million INR | 0.0% |
| 2018 FY | 976.87 Million INR | 60.08% |
| 2018 Q3 | 281.09 Million INR | 35.56% |
| 2018 Q2 | 207.34 Million INR | 0.0% |
| 2018 Q1 | 207.34 Million INR | 30.61% |
| 2017 Q3 | 158.75 Million INR | 8.46% |
| 2017 Q4 | 158.75 Million INR | 0.0% |
| 2017 FY | 610.24 Million INR | 12.14% |
| 2017 Q1 | 146.37 Million INR | 0.0% |
| 2017 Q2 | 146.37 Million INR | 0.0% |
| 2016 FY | 544.18 Million INR | -18.39% |
| 2015 FY | 666.83 Million INR | 30.78% |
| 2014 FY | 509.89 Million INR | 13.67% |
| 2013 FY | 448.58 Million INR | 32.95% |
| 2012 FY | 337.42 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sigachi Industries Limited | 3.98 Billion INR | 63.675% |
| Ind-Swift Limited | 5.02 Billion INR | 71.158% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 69.388% |
| Sakar Healthcare Limited | 1.54 Billion INR | 5.998% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 99.5% |
| Innova Captab Limited | 10.81 Billion INR | 86.598% |
| Divi's Laboratories Limited | 78.45 Billion INR | 98.153% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 88.814% |
| Morepen Laboratories Limited | 17.01 Billion INR | 91.485% |
| Mankind Pharma Limited | 103.34 Billion INR | 98.598% |
| Sequent Scientific Limited | 13.69 Billion INR | 89.42% |
| Wanbury Limited | 5.75 Billion INR | 74.825% |
| Laurus Labs Limited | 50.01 Billion INR | 97.103% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 91.397% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 93.653% |
| Alembic Limited | 1.57 Billion INR | 7.978% |
| Hikal Limited | 17.84 Billion INR | 91.879% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 97.629% |
| Neuland Laboratories Limited | 15.58 Billion INR | 90.702% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 95.797% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 98.773% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 93.205% |
| Themis Medicare Limited | 3.81 Billion INR | 62.039% |
| RPG Life Sciences Limited | 5.82 Billion INR | 75.102% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.238% |
| Lupin Limited | 196.56 Billion INR | 99.263% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 65.596% |
| Wockhardt Limited | 27.89 Billion INR | 94.804% |
| Vaishali Pharma Limited | 862.79 Million INR | -67.966% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 92.018% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 30.561% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 97.838% |
| FDC Limited | 19.42 Billion INR | 92.541% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.481% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | 6.123% |
| Eris Lifesciences Limited | 20.09 Billion INR | 92.787% |
| Venus Remedies Limited | 5.91 Billion INR | 75.497% |
| ZIM Laboratories Limited | 3.67 Billion INR | 60.568% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 81.185% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -51.527% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 91.357% |
| Shilpa Medicare Limited | 11.53 Billion INR | 87.432% |
| Albert David Limited | 3.62 Billion INR | 60.018% |
| Ajanta Pharma Limited | 42.08 Billion INR | 96.557% |
| Hester Biosciences Limited | 3.04 Billion INR | 52.414% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 86.216% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 88.298% |
| Gufic Biosciences Limited | 8.06 Billion INR | 82.035% |
| Windlas Biotech Limited | 6.3 Billion INR | 77.032% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 87.412% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | 63.369% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | 60.55% |
| Granules India Limited | 45.06 Billion INR | 96.784% |
| Aarti Drugs Limited | 25.28 Billion INR | 94.269% |
| Bal Pharma Limited | 3.39 Billion INR | 57.278% |
| Alkem Laboratories Limited | 126.67 Billion INR | 98.856% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.701% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 75.037% |
| Medicamen Biotech Limited | 1.79 Billion INR | 19.177% |
| Unichem Laboratories Limited | 16.57 Billion INR | 91.256% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | 4.949% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -261.982% |
| Valiant Laboratories Limited | 1.82 Billion INR | 20.398% |
| Orchid Pharma Limited | 8.19 Billion INR | 82.313% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 88.686% |
| Ipca Laboratories Limited | 77.05 Billion INR | 98.119% |
| Brooks Laboratories Limited | 794.86 Million INR | -82.322% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 44.099% |
| Piramal Enterprises Limited | 60.33 Billion INR | 97.598% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 98.634% |
| NATCO Pharma Limited | 40.02 Billion INR | 96.379% |
| Suven Life Sciences Limited | 116.92 Million INR | -1139.391% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -187.418% |
| Strides Pharma Science Limited | 40.51 Billion INR | 96.423% |
| Indoco Remedies Limited | 18.17 Billion INR | 92.025% |
| Alpa Laboratories Limited | 1.08 Billion INR | -33.274% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -38.899% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -91.833% |